Xuelian Zhao

Xuelian Zhao

Auto-generated profile, based on publicly available information

Xuelian Zhao

Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
MYMeiwen Yuan
Meiwen Yuan
XZXuelian Zhao
Xuelian Zhao
HWHonghao Wang
Honghao Wang
SHShangying Hu
Shangying Hu
FZFanghui Zhao
Fanghui Zhao
Background: There are no studies extrapolating the incidence and mortality of cervical cancer in China by comparing incidence and deaths pattern between geographic and age groups. Methods: We applied age-period-cohort models to assess region-level trends in incidence and mortality from 2006 to 2016, with piecewise linear regression in a Bayesian framework to predict these trends to 2030. Results: Between 2006 and 2016, age-standardized incidence rates (ASIR) for females aged 15 to 84 years increased by 3.7% (95% confidence interval, 3.1%–4.3%) annually from 11.01 to 16.41 per 100,000 females in China. In the 25 to 39 age groups, the incidence rates decreased in urban regions and inversely increased in rural regions. The age-standardized mortality rates (ASMR) increased from 3.18 to 4.83, with annual increases of about 3.6% (1.5%–5.8%). From 2017 to 2030, the ASIR is expected to increase from 17.13 (15.91–18.46) to 23.22 (20.02–27.01) by 2.5% per year (P < 0.05). Meanwhile, the average age at diagnosis is predicted to grow from 53.1 to 60.5 years. In the 15 to 54 age groups, the incidence rates decreased in urban regions but increased in rural regions. The ASMR is expected to increase consistently from 4.82 (4.38–5.31) to 9.13 (7.35–11.39) by 5.0% per year (P < 0.05). Conclusions: Cervical cancer incidence and mortality rates are projected to increase in China. In addition, the urban–rural incidence gap is estimated to widen further among young women. Impact: Cervical cancer prevention should consider the trend and diversity in incidence patterns between urban and rural regions.

17 February 2024 in International Journal of Cancer
Verified
Journal Article
Closed access
TWTian‐Meng Wen
Tian‐Meng Wen
XXXiao‐Qian Xu
Xiao‐Qian Xu
XZXue‐Lian Zhao
Xue‐Lian Zhao
CPCheng‐Hao Pan
Cheng‐Hao Pan
YFYu‐Shu Feng
Yu‐Shu Feng
FZFanghui Zhao
Fanghui Zhao

18 August 2022 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
SHShang‐Ying Hu
Shang‐Ying Hu
XZXue‐Lian Zhao
Xue‐Lian Zhao
FZFanghui Zhao
Fanghui Zhao
LWLi‐Hui Wei
Li‐Hui Wei
QZQi Zhou
Qi Zhou
RSRengaswamy Sankaranarayanan
Rengaswamy Sankaranarayanan

1 August 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SCShimin Chen
Shimin Chen
HDHongshuang Dai
Hongshuang Dai
SHShangying Hu
Shangying Hu
TGTangjie Gao
Tangjie Gao
MCMing Chen
Ming Chen
FZFanghui Zhao
Fanghui Zhao
Optimal triage option for high-risk HPV-positive (hrHPV) women remains uncertain. We aimed to utilize methylation-sensitive restriction enzyme-based quantitative PCR (MSRE-qPCR) technique and develop triple-target human gene methylation panels to improve detection of advanced cervical precancers and cancers (CIN3 +) among hrHPV women. Eighteen candidate genes were detected by MSRE-qPCR in cervical samples from hrHPV women. All possible triple-target panels from these genes were generated by logistic regression models with repeated ten-fold cross-validation on a training set of 1223 women (180 CIN3 +; 1043 < CIN3). Panels with the top two AUCs for CIN3 + on a validation set of 937 women (69 CIN3 +; 868 < CIN3) were ultimately selected for qPCR reconstruction, retesting, and retraining. Triage performance, screening efficiency and risk stratification of the selected panels were then compared with traditional triage strategies (cytology [ASCUS as the threshold, atypical squamous cells of undetermined significance], HPV16/18 genotyping, HPV16/18 genotyping combined with cytology [ASCUS]) within the validation set. Two panels were finally identified and validated for CIN3 + detection. Panel 1 includes JAM3, PCDHGB7, and SORCS1; while Panel 2 consists of PAX1, ZNF671, and ASCL1. Compared to traditional triage strategies, both panels demonstrated superior AUCs (Panel 1: 0.799; Panel 2: 0.790; Cytology: 0.532; HPV16/18 genotyping: 0.589; HPV16/18 + Cytology: 0.515; all PAUC < 0.001), with substantially higher specificities (83.06%; 86.98%; 29.49%; 72.93%; 14.52%), comparable sensitivities (76.81%; 71.01%; 76.81%; 44.93%; 88.41%), and requiring fewer colposcopies per CIN3 + case (3.77; 3.31; 12.55; 8.58; 13.16). However, Panel 1 and Panel 2 were statistically indistinguishable (PAUC = 0.603; Ratiosensitivity: 0.92 [0.76–1.13]; Ratiospecificity: 1.05 [1.01–1.08]). Unlike traditional strategies (CIN3 + risks: 5.59% ~ 17.97%), women tested negative on either panel had immediate CIN3 + risks below 3% (Panel 1: 2.17%; Panel 2: 2.58%), supporting safe deferral for at least one year. Two triple-target human gene methylation panels were successfully developed, each integrated into a single MSRE-qPCR system for one-tube detection. Both panels outperformed current triage strategies, indicating their potential as alternatives, though external validation among diverse settings is needed before clinical application.

13 August 2022 in Journal of the National Cancer Center
Verified
Journal Article
Open access
XZXuelian Zhao
Xuelian Zhao
SHShangying Hu
Shangying Hu
ZSZhao Shuang
Zhao Shuang
RRRemila Rezhake
Remila Rezhake
LHLiuye Huang
Liuye Huang
FZFanghui Zhao
Fanghui Zhao
We assessed the longitudinal risk of developing cervical intraepithelial neoplasia (CINs) with self-sampling human papillomavirus (HPV) tests, based on polymerase chain reaction (PCR) and signal amplification (careHPV), to explore the appropriate intervals for cervical cancer screening. A prospective study was conducted in China during 2017–2020. Participants were invited for PCR and careHPV tests with self-samples at baseline. Women positive in either HPV test underwent colposcopy and biopsy if necessary. Women with baseline CIN grade one (CIN1) or less were followed up over 3 years. The absolute risk was assessed by the immediate risk (IR) and cumulative risk (CR), and the relative risk was assessed by the hazard ratio (HR) with a 95% confidence interval (CI). A total of 8,126 women were included in the final analysis. Women positive for the PCR HPV test had comparable IRs of CIN2+ and CIN3+ to those positive on the careHPV test. With triage by HPV genotyping, women with HPV 16/18 infection had the highest IRs of CIN2+ (21.15%) and CIN3+ (9.67%). For CR, women negative for PCR HPV test had a lower risk of CIN2+ than that reported in women negative on careHPV test (0.57% versus 0.98%, HR = 0.58, 95% CI: 0.38, 0.87), but no significant difference was found in the CRs of CIN3+ between them (0.25% versus 0.39%, HR = 0.64, 95% CI: 0.34, 1.20). Among women with CIN1 or less at baseline, women who were persistent or recurrent positive on careHPV or PCR HPV test had a higher risk of developing CIN3+ (11.36%-14.59%), compared with women remained HPV negative from baseline throughout follow-up (≤0.28%). Routine screening with 3-year intervals is acceptable for self-sampling HPV tests based on PCR or careHPV test. Women positive on HPV16/18 triaging at baseline or with CIN1 or less at baseline while being persistent or recurrent positive on careHPV or PCR HPV test during 3-year follow-up require immediate colposcopy or treatment.

26 November 2025
Verified
Other
Open access
MYMeiwen Yuan
Meiwen Yuan
XZXuelian Zhao
Xuelian Zhao
HWHonghao Wang
Honghao Wang
SHShangying Hu
Shangying Hu
FZFanghui Zhao
Fanghui Zhao
Table S5 shows proportion of the annual number of deaths by age group between 2006 to 2016.